Etern Biopharma (Shanghai) Co. Ltd. has described bicyclic heteroaryl compounds acting as transcriptional coactivator YAP1 and/or TAZ/transcriptional enhancer factor (TEAD) interaction inhibitors reported to be useful for the treatment of cancer, fibrosis and cardiovascular disorders.
Shenzhen Forward Pharmaceuticals Co. Ltd. has synthesized quinazoline derivatives acting as GTPase KRAS (G12C mutant) inhibitors reported to be useful for the treatment of cancer, particularly lung cancer.
Harbour Biomed Ltd. has received FDA clearance of its IND application to commence a phase I trial of HBM-9033 in advanced solid tumors. Developed in collaboration with Medilink Therapeutics (Suzhou) Co. Ltd., HBM-9033 is an antibody-drug conjugate that specifically targets human mesothelin (MSLN), an upregulated tumor-associated antigen in various solid tumors, including mesothelioma, ovarian cancer, lung cancer, breast cancer and pancreatic cancers. The fully human monoclonal antibody in HBM-9033, generated from the Harbour Mice platform, binds preferably to membrane bond MSLN over soluble MSLN, which minimizes the interference of the shedding MSLN on the binding and internalization of the membrane bond MSLN.
Merck KGaA has divulged proteolysis targeting chimeras (PROTACs) compounds comprising an E3 ubiquitin ligase binding agent coupled to methionine aminopeptidase-2 (MNPEP; MetAP2) targeting moiety via a linker reported to be useful for the treatment of cancer, rheumatoid arthritis, psoriasis, osteoporosis, diabetes, obesity, malaria and benign prostatic hyperplasia, among others.
Gilead Sciences Inc. has identified protein mono-ADP-ribosyltransferase TIPARP (PARP-7; ARTD14) inhibitors reported to be useful for the treatment of cancer.
Adlai Nortye Pharmaceutical Co. Ltd. has disclosed Wnt signaling inhibitors reported to be useful for the treatment of cancer, immunological and inflammatory disorders.
Jiangsu Tasly Diyi Pharmaceutical Co. Ltd. has described Wee1-like protein kinase (Wee1) inhibitors reported to be useful for the treatment of inflammation, infection, cancer, and autoimmune disease.
Etern Biopharma (Shanghai) Co. Ltd. has divulged transcriptional coactivator YAP1 and TAZ/transcriptional enhancer factor (TEAD) interaction inhibitors reported to be useful for the treatment of cancer.
Broncus Holding Corp. successfully completed a clinical study of the world’s first transbronchial radiofrequency ablation system for lung cancer treatment.
The old Viralytics Ltd. team is back together again in a new company called Immvirx Pty Ltd. that is developing oncolytic viruses to tackle the four most deadly cancers, Immvirx CEO and co-founder Malcolm McColl told BioWorld.
